The global glioblastoma multiforme (GBM) treatment market is experiencing significant growth, driven by the urgent need for effective therapies for this highly aggressive and lethal form of brain cancer. Glioblastoma multiforme, classified as a grade IV astrocytoma, represents the most common and deadliest primary brain tumor in adults. Its complex nature and rapid progression necessitate a multifaceted treatment approach, combining surgery, radiation therapy, and chemotherapy. The market is witnessing a surge in the development of novel therapeutic approaches, including targeted therapies and immunotherapies. Advances in molecular biology have led to the identification of specific genetic mutations and pathways involved in GBM, paving the way for precision medicine.
Data Bridge Market Research analyses that Glioblastoma Multiforme Treatment Market will grow at a CAGR of 8.1% during the forecast period of 2022 to 2029.
Below are the Top Five Glioblastoma Multiforme Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
F. Hoffmann-La Roche Ltd., commonly known as Roche, is a leading player in the global glioblastoma multiforme (GBM) treatment market, leveraging its extensive expertise in oncology and innovative drug development. Roche's market presence is bolstered by its strong portfolio of targeted therapies and diagnostics, aimed at improving patient outcomes for those suffering from this aggressive form of brain cancer. The company’s key offerings, such as Avastin (bevacizumab), have shown effectiveness in slowing disease progression and improving quality of life for GBM patients.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In February 2023, Roche announced the launch of two new antibodies designed to identify key clinical mutations in brain cancer patients. The IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody are now available to help determine the mutation status in individuals diagnosed with brain cancer.
|
|
2.
|
Amgen Inc.
|
Amgen Inc. is a prominent player in the global glioblastoma multiforme (GBM) treatment market, known for its cutting-edge research and development in oncology. The company leverages its extensive biopharmaceutical expertise to develop innovative therapies aimed at improving outcomes for patients with this aggressive brain cancer. Amgen’s focus on targeted therapies and immuno-oncology positions it well within the GBM treatment landscape, where personalized and precise treatment options are crucial.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In July 2019, Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) is available in the United States (U.S.). This launch will enhance the sales of the product in the region
|
|
3.
|
Merck & Co., Inc.
|
The company's strong focus on oncology and immuno-oncology therapies positions it well to address the complexities of GBM, an aggressive and difficult-to-treat brain cancer. Merck's flagship product, Keytruda (pembrolizumab), is a leading immunotherapy that has shown promise in various cancer types, including GBM. Keytruda works by harnessing the body's immune system to target and destroy cancer cells, offering a novel approach to GBM treatment. Merck's commitment to research and development is evident in its extensive pipeline of investigational therapies for GBM.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In November 2021, Merck & Co., Inc. announced that they participated in virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021. This conference has given a platform to showcase the performance of the company and help in future business expansion.
|
|
4.
|
Pfizer Inc.
|
Pfizer Inc. is a significant player in the global glioblastoma multiforme (GBM) treatment market, leveraging its extensive expertise in oncology and innovative drug development to address the challenges posed by this aggressive brain cancer. Pfizer’s diverse portfolio includes a range of targeted therapies and chemotherapeutic agents that are utilized in the treatment of various cancers, including GBM. The company’s focus on precision medicine and targeted treatment approaches aligns well with the need for more effective GBM therapies.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.
|
|
5.
|
Varian Medical Systems, Inc.
|
Varian Medical Systems, Inc., a subsidiary of Siemens Healthineers, is a leading player in the global glioblastoma multiforme (GBM) treatment market, primarily known for its advanced radiation therapy technologies. Varian's innovative solutions, such as linear accelerators and radiosurgery systems, are widely used in the treatment of GBM, offering precise and effective options to target and destroy cancer cells. Varian's flagship products, including the TrueBeam and Edge radiosurgery systems, provide high-dose radiation with pinpoint accuracy, minimizing damage to surrounding healthy tissue.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In January 2022, Varian, together with its parent company, Siemens Healthineers, announced a long-term ten-year strategic partnership with Oulu University Hospital in Finland to build a comprehensive digital, diagnostic and therapeutic ecosystem that addresses the entire cancer treatment pathway and advances the quality of care for cancer patients in Northern Finland. This will enhance their R&D portfolio.
|
Conclusion
The global glioblastoma multiforme (GBM) treatment market is on a promising trajectory of growth, fueled by significant advancements in therapeutic approaches, technology, and collaborative efforts across the healthcare sector. Key drivers such as the rising incidence of GBM, innovative therapies, and increased government and institutional support are propelling the market forward. Companies like Varian Medical Systems, F. Hoffmann-La Roche Ltd., Amgen Inc., Merck & Co., Inc., and Pfizer Inc. are at the forefront, leveraging their expertise in oncology and cutting-edge technologies to improve treatment outcomes for GBM patients.
